The direct thrombin inhibitor ximelagatran/melagatran

A systematic review on clinical applications and an evidence based assessment of risk benefit profile

Luca Testa, Ravinai Bhindi, Pierfrancesco Agostoni, Antonio Abbate, Guiseppe G L Biondi Zoccai, William J. Van Gaal

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

The direct thrombin inhibitor, ximelagatran, and its active form, melagatran (X/M), have been compared against conventional anticoagulant therapy (CAT) in many clinical settings. Their risk-benefit profile drove large debate until withdrawal by the manufacturer. A systematic review of all published randomized trials has been performed and a meta-analysis of randomised controlled trial (RCT) of X/M versus CAT. Major medical databases were searched for RCTs. Major adverse events (MAE: all cause death, nonfatal myocardial infarction, nonfatal thromboembolic stroke, pulmonary embolism), major bleeds (MB), minor bleeds and the rate of hepatotoxicity (HT) were compared. In terms of efficacy, X/M was at least as effective as, or even superior to, CAT. In terms of safety, the overall risk of MAE, MB, minor bleeds and HT was not significantly different for X/M compared with CAT. According to individual clinical settings, X/M was associated with a lower risk of MB but a prohibitive higher risk of HT in those clinical settings requiring prolonged treatment.

Original languageEnglish
Pages (from-to)397-406
Number of pages10
JournalExpert Opinion on Drug Safety
Volume6
Issue number4
DOIs
Publication statusPublished - Jul 2007

Fingerprint

Antithrombins
Anticoagulants
Therapeutics
Pulmonary Embolism
Meta-Analysis
Cause of Death
Randomized Controlled Trials
Stroke
Myocardial Infarction
Databases
Safety
ximelagatran
melagatran

Keywords

  • Anticoagulants
  • Melagatran
  • Meta-analysis
  • Thrombosis
  • Ximelagatran

ASJC Scopus subject areas

  • Pharmacology

Cite this

The direct thrombin inhibitor ximelagatran/melagatran : A systematic review on clinical applications and an evidence based assessment of risk benefit profile. / Testa, Luca; Bhindi, Ravinai; Agostoni, Pierfrancesco; Abbate, Antonio; Biondi Zoccai, Guiseppe G L; Van Gaal, William J.

In: Expert Opinion on Drug Safety, Vol. 6, No. 4, 07.2007, p. 397-406.

Research output: Contribution to journalArticle

Testa, Luca ; Bhindi, Ravinai ; Agostoni, Pierfrancesco ; Abbate, Antonio ; Biondi Zoccai, Guiseppe G L ; Van Gaal, William J. / The direct thrombin inhibitor ximelagatran/melagatran : A systematic review on clinical applications and an evidence based assessment of risk benefit profile. In: Expert Opinion on Drug Safety. 2007 ; Vol. 6, No. 4. pp. 397-406.
@article{c0dbac7ffdcb4bedaca56e1bfdfe6d43,
title = "The direct thrombin inhibitor ximelagatran/melagatran: A systematic review on clinical applications and an evidence based assessment of risk benefit profile",
abstract = "The direct thrombin inhibitor, ximelagatran, and its active form, melagatran (X/M), have been compared against conventional anticoagulant therapy (CAT) in many clinical settings. Their risk-benefit profile drove large debate until withdrawal by the manufacturer. A systematic review of all published randomized trials has been performed and a meta-analysis of randomised controlled trial (RCT) of X/M versus CAT. Major medical databases were searched for RCTs. Major adverse events (MAE: all cause death, nonfatal myocardial infarction, nonfatal thromboembolic stroke, pulmonary embolism), major bleeds (MB), minor bleeds and the rate of hepatotoxicity (HT) were compared. In terms of efficacy, X/M was at least as effective as, or even superior to, CAT. In terms of safety, the overall risk of MAE, MB, minor bleeds and HT was not significantly different for X/M compared with CAT. According to individual clinical settings, X/M was associated with a lower risk of MB but a prohibitive higher risk of HT in those clinical settings requiring prolonged treatment.",
keywords = "Anticoagulants, Melagatran, Meta-analysis, Thrombosis, Ximelagatran",
author = "Luca Testa and Ravinai Bhindi and Pierfrancesco Agostoni and Antonio Abbate and {Biondi Zoccai}, {Guiseppe G L} and {Van Gaal}, {William J.}",
year = "2007",
month = "7",
doi = "10.1517/14740338.6.4.397",
language = "English",
volume = "6",
pages = "397--406",
journal = "Expert Opinion on Drug Safety",
issn = "1474-0338",
publisher = "Taylor and Francis Ltd.",
number = "4",

}

TY - JOUR

T1 - The direct thrombin inhibitor ximelagatran/melagatran

T2 - A systematic review on clinical applications and an evidence based assessment of risk benefit profile

AU - Testa, Luca

AU - Bhindi, Ravinai

AU - Agostoni, Pierfrancesco

AU - Abbate, Antonio

AU - Biondi Zoccai, Guiseppe G L

AU - Van Gaal, William J.

PY - 2007/7

Y1 - 2007/7

N2 - The direct thrombin inhibitor, ximelagatran, and its active form, melagatran (X/M), have been compared against conventional anticoagulant therapy (CAT) in many clinical settings. Their risk-benefit profile drove large debate until withdrawal by the manufacturer. A systematic review of all published randomized trials has been performed and a meta-analysis of randomised controlled trial (RCT) of X/M versus CAT. Major medical databases were searched for RCTs. Major adverse events (MAE: all cause death, nonfatal myocardial infarction, nonfatal thromboembolic stroke, pulmonary embolism), major bleeds (MB), minor bleeds and the rate of hepatotoxicity (HT) were compared. In terms of efficacy, X/M was at least as effective as, or even superior to, CAT. In terms of safety, the overall risk of MAE, MB, minor bleeds and HT was not significantly different for X/M compared with CAT. According to individual clinical settings, X/M was associated with a lower risk of MB but a prohibitive higher risk of HT in those clinical settings requiring prolonged treatment.

AB - The direct thrombin inhibitor, ximelagatran, and its active form, melagatran (X/M), have been compared against conventional anticoagulant therapy (CAT) in many clinical settings. Their risk-benefit profile drove large debate until withdrawal by the manufacturer. A systematic review of all published randomized trials has been performed and a meta-analysis of randomised controlled trial (RCT) of X/M versus CAT. Major medical databases were searched for RCTs. Major adverse events (MAE: all cause death, nonfatal myocardial infarction, nonfatal thromboembolic stroke, pulmonary embolism), major bleeds (MB), minor bleeds and the rate of hepatotoxicity (HT) were compared. In terms of efficacy, X/M was at least as effective as, or even superior to, CAT. In terms of safety, the overall risk of MAE, MB, minor bleeds and HT was not significantly different for X/M compared with CAT. According to individual clinical settings, X/M was associated with a lower risk of MB but a prohibitive higher risk of HT in those clinical settings requiring prolonged treatment.

KW - Anticoagulants

KW - Melagatran

KW - Meta-analysis

KW - Thrombosis

KW - Ximelagatran

UR - http://www.scopus.com/inward/record.url?scp=34548473336&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548473336&partnerID=8YFLogxK

U2 - 10.1517/14740338.6.4.397

DO - 10.1517/14740338.6.4.397

M3 - Article

VL - 6

SP - 397

EP - 406

JO - Expert Opinion on Drug Safety

JF - Expert Opinion on Drug Safety

SN - 1474-0338

IS - 4

ER -